MX2012004499A - Esterilizacion de hidrogeles biodegradables. - Google Patents

Esterilizacion de hidrogeles biodegradables.

Info

Publication number
MX2012004499A
MX2012004499A MX2012004499A MX2012004499A MX2012004499A MX 2012004499 A MX2012004499 A MX 2012004499A MX 2012004499 A MX2012004499 A MX 2012004499A MX 2012004499 A MX2012004499 A MX 2012004499A MX 2012004499 A MX2012004499 A MX 2012004499A
Authority
MX
Mexico
Prior art keywords
sterilization
biodegradable hydrogels
hydrogels
biodegradable
withfunctionally
Prior art date
Application number
MX2012004499A
Other languages
English (en)
Inventor
Ulrich Hersel
Harald Rau
Tobias Voigt
Original Assignee
Ascendis Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma As filed Critical Ascendis Pharma As
Publication of MX2012004499A publication Critical patent/MX2012004499A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6903—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being semi-solid, e.g. an ointment, a gel, a hydrogel or a solidifying gel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/0005—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts
    • A61L2/0011—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor for pharmaceuticals, biologicals or living parts using physical methods
    • A61L2/0029—Radiation
    • A61L2/0035—Gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/08—Radiation
    • A61L2/081—Gamma radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2/00—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor
    • A61L2/02—Methods or apparatus for disinfecting or sterilising materials or objects other than foodstuffs or contact lenses; Accessories therefor using physical phenomena
    • A61L2/08—Radiation
    • A61L2/10—Ultraviolet radiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L71/00—Compositions of polyethers obtained by reactions forming an ether link in the main chain; Compositions of derivatives of such polymers
    • C08L71/02—Polyalkylene oxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L2202/00—Aspects relating to methods or apparatus for disinfecting or sterilising materials or objects
    • A61L2202/20—Targets to be treated
    • A61L2202/21—Pharmaceuticals, e.g. medicaments, artificial body parts
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Polymers & Plastics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Preparation (AREA)
  • Materials For Medical Uses (AREA)
  • Colloid Chemistry (AREA)
  • Polyethers (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Apparatus For Disinfection Or Sterilisation (AREA)

Abstract

La presente invención se refiere a un proceso de esterilización terminal para los hidrogeles insolubles a base de PEG biodegradables utilizando irradiación. La presencia de un solvente protector asegura que el hidrogel permanezca intacto, con las propiedades tridimensionales y fisicoquímicas conservadas funcionalmente.
MX2012004499A 2009-10-29 2010-10-28 Esterilizacion de hidrogeles biodegradables. MX2012004499A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09174526 2009-10-29
PCT/EP2010/066404 WO2011051406A1 (en) 2009-10-29 2010-10-28 Sterilization of biodegradable hydrogels

Publications (1)

Publication Number Publication Date
MX2012004499A true MX2012004499A (es) 2012-05-29

Family

ID=42040569

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2012004499A MX2012004499A (es) 2009-10-29 2010-10-28 Esterilizacion de hidrogeles biodegradables.

Country Status (16)

Country Link
US (2) US8986609B2 (es)
EP (1) EP2493514B1 (es)
JP (1) JP5893566B2 (es)
KR (1) KR101756493B1 (es)
CN (1) CN102686245B (es)
AU (1) AU2010311421B2 (es)
BR (1) BR112012010249A2 (es)
CA (1) CA2776723C (es)
HK (1) HK1176311A1 (es)
IL (1) IL218779A (es)
MX (1) MX2012004499A (es)
MY (1) MY157640A (es)
NZ (1) NZ599583A (es)
RU (1) RU2558847C9 (es)
WO (1) WO2011051406A1 (es)
ZA (1) ZA201203032B (es)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2769162C (en) * 2009-07-31 2017-12-05 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
KR101759499B1 (ko) 2009-07-31 2017-07-19 사노피-아벤티스 도이칠란트 게엠베하 지속형 인슐린 조성물
EP2459228B1 (en) 2009-07-31 2020-03-04 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an insulin linker conjugate
WO2011044421A1 (en) 2009-10-08 2011-04-14 C. R. Bard, Inc. Spacers for use with an ultrasound probe
WO2011051406A1 (en) * 2009-10-29 2011-05-05 Ascendis Pharma As Sterilization of biodegradable hydrogels
CA2806353A1 (en) 2010-08-09 2012-02-16 C.R. Bard Inc. Support and cover structures for an ultrasound probe head
EP2438930A1 (en) 2010-09-17 2012-04-11 Sanofi-Aventis Deutschland GmbH Prodrugs comprising an exendin linker conjugate
USD699359S1 (en) 2011-08-09 2014-02-11 C. R. Bard, Inc. Ultrasound probe head
US11021733B2 (en) 2011-09-26 2021-06-01 Qiagen Gmbh Stabilization and isolation of extracellular nucleic acids
AU2012314515B2 (en) 2011-09-26 2018-03-15 Preanalytix Gmbh Stabilisation and isolation of extracellular nucleic acids
US9211107B2 (en) 2011-11-07 2015-12-15 C. R. Bard, Inc. Ruggedized ultrasound hydrogel insert
EP2861153A4 (en) 2012-06-15 2016-10-19 Bard Inc C R APPARATUS AND METHODS FOR DETECTION OF A REMOVABLE CAP ON AN ULTRASONIC PROBE
US10724074B2 (en) 2012-09-25 2020-07-28 Qiagen Gmbh Stabilisation of biological samples
EP2910600B1 (en) * 2012-10-19 2017-12-06 Daicel Polymer Ltd. Cellulose ester composition
MX2015012114A (es) 2013-03-08 2016-01-12 Genzyme Corp Fabricacion continua integrada de principios activos proteinicos terapeuticos.
EP2976425B1 (en) 2013-03-18 2019-11-06 Qiagen GmbH Stabilization and isolation of extracellular nucleic acids
JP6381628B2 (ja) 2013-03-18 2018-08-29 キアゲン ゲーエムベーハー 生物試料の安定化
TWI709570B (zh) 2014-01-17 2020-11-11 美商健臻公司 無菌層析法及製法
TWI709569B (zh) * 2014-01-17 2020-11-11 美商健臻公司 無菌層析樹脂及其用於製造方法的用途
US20170274012A1 (en) * 2014-09-03 2017-09-28 Entegrion, Inc. Acceleration of Reconstitution of Plasma Powder by Mixing with Small Beads
IL254158B2 (en) 2015-02-25 2023-04-01 Decision Sciences Medical Company Llc Acoustic signal transmission couplers and coupling means
CN107750274A (zh) 2015-06-08 2018-03-02 康宁股份有限公司 用于水凝胶微载体的干燥制剂
US11203777B2 (en) 2015-11-20 2021-12-21 Qiagen Gmbh Method of preparing sterilized compositions for stabilization of extracellular nucleic acids
JOP20190245A1 (ar) 2017-04-20 2019-10-15 Novartis Ag أنظمة توصيل إطلاق مستدام تتضمن روابط بلا أثر لنقطة الربط
JP2021536353A (ja) 2018-08-31 2021-12-27 ジェンザイム・コーポレーション 無菌クロマトグラフィー樹脂および製造方法におけるその使用
TW202027794A (zh) 2018-10-03 2020-08-01 瑞士商諾華公司 血管生成素樣３多肽之持續遞送
US20200248124A1 (en) 2019-02-05 2020-08-06 Corning Incorporated Methods of culturing cells on woven cell culture substrates and bioreactors using the same
US20220134608A1 (en) * 2019-03-06 2022-05-05 Decision Sciences Medical Company, LLC Methods for manufacturing and distributing semi-rigid acoustic coupling articles and packaging for ultrasound imaging
WO2020219705A1 (en) 2019-04-23 2020-10-29 Allan Wegner Semi-rigid acoustic coupling articles for ultrasound diagnostic and treatment applications
US11118151B2 (en) 2019-11-05 2021-09-14 Corning Incorporated Fixed bed bioreactor and methods of using the same
CN111171339B (zh) * 2019-12-18 2022-07-05 青岛大学 一种可注射水凝胶前驱液的制备方法可注射水凝胶及其应用
ES2952213T3 (es) 2020-02-06 2023-10-30 Ocular Therapeutix Inc Composiciones y métodos para tratar enfermedades oculares
MX2022010333A (es) 2020-03-25 2022-12-08 Ocular Therapeutix Inc Implante ocular que contiene un inhibidor de la tirosina cinasa.
WO2021224169A1 (en) 2020-05-04 2021-11-11 Ascendis Pharma A/S Hydrogel irradiation
CN115160599B (zh) * 2022-08-03 2023-06-02 苏州大学 一种按需降解的聚多巴胺交联聚乙二醇水凝胶材料及其制备方法与应用

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2539135B1 (fr) 1983-01-11 1986-02-28 Essilor Int Hydrogels de polyurethane et procede de fabrication
JPH0611290B2 (ja) 1986-11-05 1994-02-16 住友ベークライト株式会社 ポリビニルアルコ−ルゲルのγ線滅菌法
US5634943A (en) 1990-07-12 1997-06-03 University Of Miami Injectable polyethylene oxide gel implant and method for production
US5514379A (en) 1992-08-07 1996-05-07 The General Hospital Corporation Hydrogel compositions and methods of use
US5705780A (en) 1995-06-02 1998-01-06 Howmedica Inc. Dehydration of hydrogels
US20020064546A1 (en) 1996-09-13 2002-05-30 J. Milton Harris Degradable poly(ethylene glycol) hydrogels with controlled half-life and precursors therefor
US6566406B1 (en) 1998-12-04 2003-05-20 Incept, Llc Biocompatible crosslinked polymers
GB9724055D0 (en) 1997-11-15 1998-01-14 Dow Corning Sa Curable polysiloxane compositions
AU1249001A (en) 1999-06-11 2001-01-31 Nektar Therapeutics Al, Corporation Hydrogels derived from chitosan and poly(ethylene glycol) or related polymers
CN1121876C (zh) * 1999-08-12 2003-09-24 中国原子能科学研究院 水凝胶复合型创伤敷料及其辐射合成方法
US6537569B2 (en) 2001-02-14 2003-03-25 Microvention, Inc. Radiation cross-linked hydrogels
EP1306127B2 (en) 2001-10-26 2011-09-07 OctoPlus PolyActive Sciences B.V. Method for the preparation of purified microparticles
EP1525890A1 (en) 2003-10-02 2005-04-27 Complex Biosystems GmbH Protein-Proteophore complexes
DK1732607T3 (da) 2004-03-23 2019-07-22 Ascendis Pharma Gmbh Polymer-prodrug med en selvofrende linker
US7968085B2 (en) 2004-07-05 2011-06-28 Ascendis Pharma A/S Hydrogel formulations
JPWO2006038462A1 (ja) 2004-10-01 2008-05-15 国立大学法人九州大学 新規ステロイド産生細胞
GB2427360A (en) 2005-06-22 2006-12-27 Complex Biosystems Gmbh Aliphatic prodrug linker
JP2008228744A (ja) * 2005-06-23 2008-10-02 Osaka Prefecture Univ 生体由来移植用組織の石灰化を抑制するための処理方法および処理された組織
EP1840152B1 (en) 2006-03-31 2009-07-08 Sony Deutschland Gmbh A method of forming a crosslinked polymer gel
US20070275030A1 (en) * 2006-05-25 2007-11-29 The General Hospital Corporation Dba Massachusetts General Hospital Anti-cross-linking agents and methods for inhibiting cross-linking of injectable hydrogel formulations
US9353170B2 (en) 2007-06-08 2016-05-31 Sanofi-Aventis Deutschland Gmbh Long-acting transient polymer conjugates of exendin
US8318695B2 (en) 2007-07-30 2012-11-27 Allergan, Inc. Tunably crosslinked polysaccharide compositions
DK2237799T3 (da) 2008-02-01 2019-06-11 Ascendis Pharma As Prodrug omfattende en selv-spaltbar linker
EP2247645B1 (en) * 2008-02-13 2017-12-06 Hyperbranch Medical Technology, Inc. Crosslinked polyalkyleneimine hydrogels with tunable degradation rates
SI2279007T1 (sl) 2008-04-29 2016-09-30 Ascendis Pharma Growth Disorders Division A/S Spojine pegiliranega rekombinantnega humanega rastnega hormona
AU2010220324A1 (en) 2009-03-05 2011-09-01 Ascendis Pharma As Interferon alpha carrier prodrugs
CA2769162C (en) 2009-07-31 2017-12-05 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
WO2011051406A1 (en) * 2009-10-29 2011-05-05 Ascendis Pharma As Sterilization of biodegradable hydrogels

Also Published As

Publication number Publication date
BR112012010249A2 (pt) 2015-09-22
EP2493514A1 (en) 2012-09-05
CN102686245B (zh) 2015-09-30
NZ599583A (en) 2013-09-27
RU2012121915A (ru) 2013-12-10
AU2010311421A1 (en) 2012-04-12
WO2011051406A1 (en) 2011-05-05
CA2776723A1 (en) 2011-05-05
HK1176311A1 (zh) 2013-07-26
US8986609B2 (en) 2015-03-24
CA2776723C (en) 2018-09-25
KR20120123260A (ko) 2012-11-08
IL218779A (en) 2015-08-31
JP2013509216A (ja) 2013-03-14
IL218779A0 (en) 2012-06-28
US20120253071A1 (en) 2012-10-04
RU2558847C2 (ru) 2015-08-10
KR101756493B1 (ko) 2017-07-10
CN102686245A (zh) 2012-09-19
ZA201203032B (en) 2013-01-30
RU2558847C9 (ru) 2016-07-20
MY157640A (en) 2016-07-15
JP5893566B2 (ja) 2016-03-23
EP2493514B1 (en) 2018-08-22
AU2010311421B2 (en) 2014-11-20
US20150196667A1 (en) 2015-07-16
US9278139B2 (en) 2016-03-08

Similar Documents

Publication Publication Date Title
MX2012004499A (es) Esterilizacion de hidrogeles biodegradables.
AU2018200955B2 (en) Optimal maize loci
IL217743A (en) Bio-biodegradable non-soluble water based on poly (ethylene glycol)
MX2011007572A (es) Cubiertas externas reusables para articulos absorbentes para llevar puestos.
EP2477985A4 (en) CANCER TREATMENT
MX2012006549A (es) Composiciones y metodos que comprenden variantes de proteasa.
MX2013012920A (es) Composiciones que comprenden particulas de hidrogel.
MY170537A (en) Silicone hydrogel contact lenses for sustained release of beneficial polymers
UA105785C2 (uk) Спосіб очищення ліпопептидів
MX2011007576A (es) Articulos absorbentes reusables para llevar puestos con sistema secundario de fijacion.
EP2438193A4 (en) METHODS FOR ASSESSING THE RISKS OF BREAST CANCER
TN2011000647A1 (en) Fused imidazoles and compositions comprising them for the treatment of parasitic diseases such as e.g. malaria
MX2011011730A (es) Micelas polimericas que contienen sn-38 para el tratamiento de cancer.
EP2934380A4 (en) FIBRO-INTEGRATED HYDROGELS FOR TISSUE TISSUE TREATMENT
BR112013009648A2 (pt) método de comunicação móvel e estação de base de rádio
IN2012DN01929A (es)
EP2597949A4 (en) SUBMIKROMETERZUSAMMENSETZUNGEN
MX369983B (es) Plantas que se reproducen vía gametos no reducidos.
MY156873A (en) Novel forms of a multicyclic compound
MX2012002252A (es) Reparacion del cartilago.
MX2011010046A (es) Derivados de diaminopteridina.
MX2012007776A (es) Espandex con alta uniformidad.
IN2012DN01846A (es)
MX2009008368A (es) Metodos para preparar aminas halogenadas.
TN2011000486A1 (en) Fertilization modulation compounds and process for implementing them

Legal Events

Date Code Title Description
FG Grant or registration